Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease.
about
Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways4-Hydroxy-nonenal-A Bioactive Lipid Peroxidation ProductThe Impact of Non-Enzymatic Reactions and Enzyme Promiscuity on Cellular Metabolism during (Oxidative) Stress ConditionsMass spectrometry of fatty aldehydesOxidative stress and epilepsy: literature reviewRedox control of microglial function: molecular mechanisms and functional significanceA possible role of acrolein in diabetic retinopathy: involvement of a VEGF/TGFβ signaling pathway of the retinal pigment epithelium in hyperglycemiaRoles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease.Synchrotron infrared microspectroscopy detecting the evolution of Huntington's disease neuropathology and suggesting unique correlates of dysfunction in white versus gray brain matter.Lipids and lipidomics in brain injury and diseasesRedox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's diseaseOxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment.Oxidative stress and mitochondrial dysfunction in Alzheimer's disease.Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formationOxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.Oxidative stress in the progression of Alzheimer disease in the frontal cortex.Glutathionylated 4-hydroxy-2-(E)-alkenal enantiomers in rat organs and their contributions toward the disposal of 4-hydroxy-2-(E)-nonenal in rat liver.Fourier transform infrared imaging showing reduced unsaturated lipid content in the hippocampus of a mouse model of Alzheimer's disease.Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicityChronic treatment with a smart antioxidative nanoparticle for inhibition of amyloid plaque propagation in Tg2576 mouse model of Alzheimer's disease.Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer diseaseNOX activity is increased in mild cognitive impairmentPathological correlations between traumatic brain injury and chronic neurodegenerative diseases.Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer diseaseA potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease.Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brainMitochondrial dysfunction and cellular metabolic deficiency in Alzheimer's diseaseTargeting aldehyde dehydrogenase 2: new therapeutic opportunities.Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer's disease.Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progressionNew approaches to treating Alzheimer's diseaseDNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes.The chromatographic assay of 4-hydroxynonenal as a biomarker of diseases by means of MEPS and HPLC technique.Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain.Acute systemic accumulation of acrolein in mice by inhalation at a concentration similar to that in cigarette smokeElevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease.Interactions of glutathione transferases with 4-hydroxynonenal.Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update.Application of medical and analytical methods in Lyme borreliosis monitoring.
P2860
Q26779424-4E244A84-6D56-46D3-BDA8-5FF70E2E3211Q26782039-82AF2189-A27F-4532-926D-3CA5A11085BBQ26785889-BA71E6D8-21E8-42F2-BC79-3AC6AB685491Q26852525-3DBFBA89-9E3E-427B-B70B-AF646C3FAC32Q26996304-B7C90679-56C9-49F8-A1B1-F592BA867F5CQ27000279-0C3E77CF-3517-430C-A661-761E8BED3149Q28647896-F0F690AE-A421-436F-87D0-A22B2A9E6B9FQ30394816-5B3ACE85-7E85-4D72-8D2C-8764F87369BAQ30406678-2802E98F-F2CA-4517-9515-2504CDABD7C1Q33247769-EE10A301-092D-4957-A58C-CBBF6EB85124Q33494148-7C78F179-D76C-468C-B048-A0C52B08F794Q33506441-5F9F51DF-008E-46B0-BBE5-4CFFEA73F906Q33555956-567F1619-D34B-4E0D-8766-555DF071F764Q33608218-72C1883A-532C-49FB-9697-D12E51FB1276Q33639885-AC1D2D8A-28E8-4A7B-BC21-8603B7AEC593Q33680790-F1D59EE2-9CF5-424F-AFEC-0CBC396854CFQ33696227-DFF12C4D-BF09-433F-8777-CDEF8E66AC2FQ33764514-0DCE6DD1-6018-469C-96D2-5BD28568337AQ33784466-3FC30BAA-AEC8-4C22-9FFF-B44EA544BF45Q33812886-DBACAF5F-7577-4F31-9D7A-2540BB2ED92AQ33816311-D224868C-4C30-4EDC-8295-5B16F661963AQ33830110-6FF5C671-879B-4012-8212-9BCCB89B2699Q33891870-F695BD81-BF92-4010-90AE-AD1859BDD5DAQ33897525-CF0BDF40-A346-42F8-A4A8-CB781DC1DA15Q33897528-31A7A5D5-E72D-47AB-A525-6129EC3F1095Q33915362-AB405E0F-184D-4C2A-A51D-BB4C624C8A3DQ34268519-A4FDCC3D-1587-4872-9B23-844B3B63F92CQ34299120-76181BCB-2A49-432C-B12C-9DA29912D01AQ34395219-280D0262-79BD-4823-9D81-4B3778ABDC8CQ34440371-DD2876A2-0B8E-4844-8FE6-25B02BE74B14Q34512386-56A4B41D-4943-4E2B-9BE1-84F7726F80C0Q35081742-1A757056-27F8-4831-B481-1B8EA32D2DDFQ35098038-2F069D25-ACF8-44B5-B5AF-3E3B4DA1B9CCQ35243359-DDEC2C2B-BB6E-4697-82AE-DA35059A7325Q35286714-C56421C3-39BD-48A5-A43A-2853E8547E28Q35427617-4D9956B7-C2F1-48C7-98B0-2441B8501C1BQ35458379-E36A6636-F640-4920-AA32-1B5D52427202Q35731685-4FDD6F73-4E6F-48DF-9FC3-7C26FAD9E1C8Q35738877-04CAA0BE-871C-4601-B935-CBFADE6692ABQ35761669-220CD4AF-CAA2-4E3E-A724-36643B11CF27
P2860
Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Increased levels of 4-hydroxyn ...... and early Alzheimer's disease.
@en
Increased levels of 4-hydroxyn ...... and early Alzheimer's disease.
@nl
type
label
Increased levels of 4-hydroxyn ...... and early Alzheimer's disease.
@en
Increased levels of 4-hydroxyn ...... and early Alzheimer's disease.
@nl
prefLabel
Increased levels of 4-hydroxyn ...... and early Alzheimer's disease.
@en
Increased levels of 4-hydroxyn ...... and early Alzheimer's disease.
@nl
P2093
P1476
Increased levels of 4-hydroxyn ...... and early Alzheimer's disease.
@en
P2093
Bert C Lynn
Mark A Lovell
Taufika Islam Williams
William R Markesbery
P304
P356
10.1016/J.NEUROBIOLAGING.2005.06.004
P577
2005-07-01T00:00:00Z